Many neurological ailments cannot be detected until their later stages of progression. With variety of potential therapies for Alzheimer’s Disease within clinical trials having failed in recent years, the increasing interest in early detection of neurological ailments is increasing. One always hopes that early treatment would be more effective.
Therefore, many scientists and engineers are working on devices that can help to identify biomarkers of early neurological ailment progression to enable timely diagnoses as well as early treatment. One such biomarker is eye-motion. Many studies have reported that progressive neurological ailments can heavily impact the way the eye moves.
However, eye-tracking technologies that are currently available cannot detect subtle disruptions in eye-motion that may be associated with an early stage of neurological ailment. Berkeley, California-based C. Light Technologies has developed a new eye-tracking system that can delineate between different stages of ailment severity in multiple sclerosis (MS) patients.
Dr. Christy Sheehy and Dr. Zachary Helft, co-founders of C. Light Technologies, have confirmed that their platform works.